Filtered By:
Drug: Aspirin
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 5437 results found since Jan 2013.
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial
CONCLUSIONS: Discontinuing aspirin treatment at 24-28 weeks in women with a UtAPI ≤90th percentile was non-inferior to continuing aspirin treatment until 36 weeks for preventing preterm pre-eclampsia.PMID:37555464 | DOI:10.1111/1471-0528.17631
Source: BJOG : An International Journal of Obstetrics and Gynaecology - August 9, 2023 Category: OBGYN Authors: Erika Bonacina Pablo Garcia-Manau Monica L ópez Sara Caami ña Àngels Vives Eva Lopez-Quesada Marta Ricart Anna Maroto Laura de Mingo Elena Pintado Laura Castillo-Ribelles Lourdes Mart ín Alicia Rodriguez-Zurita Esperanza Garcia Mar Pallarols Laia Vida Source Type: research
Compliance-adjusted estimates of aspirin effects in older persons in the ASPREE randomized trial
Am J Epidemiol. 2023 Aug 8:kwad168. doi: 10.1093/aje/kwad168. Online ahead of print.ABSTRACTThe ASPirin in Reducing Events in the Elderly (ASPREE) trial recruited 19,114 participants across Australia and the United States during 2010-14. Participants were randomized to receive either 100mg aspirin daily or matching placebo, with disability-free survival as the primary outcome. During a median 4.7 years of follow-up, 37% of participants in the aspirin group permanently ceased taking their study medication and 10% commenced open label aspirin (OLA). In the placebo group, 35% and 11% ceased study medication and commenced OLA,...
Source: Am J Epidemiol - August 8, 2023 Category: Epidemiology Authors: C L Smith J Kasza R L Woods J E Lockery B Kirpach C M Reid E Storey M R Nelson R C Shah S G Orchard M E Ernst A M Tonkin A M Murray J J McNeil R Wolfe Source Type: research
Fixed-Dose Combination Therapy for Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-analysis
CONCLUSIONS: A fixed-dose combination treatment strategy is effective and safe at preventing cardiovascular disease, irrespective of eGFR but relative and absolute risk reductions are larger in individuals with low eGFR.PMID:37550842 | DOI:10.2215/CJN.0000000000000251
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 8, 2023 Category: Urology & Nephrology Authors: Sadaf G Sepanlou Johannes F E Mann Philip Joseph Prem Pais Peggy Gao Maryam Sharafkhah Gholamreza Roshandel Salim Yusuf Reza Malekzadeh Source Type: research
Compliance-adjusted estimates of aspirin effects in older persons in the ASPREE randomized trial
Am J Epidemiol. 2023 Aug 8:kwad168. doi: 10.1093/aje/kwad168. Online ahead of print.ABSTRACTThe ASPirin in Reducing Events in the Elderly (ASPREE) trial recruited 19,114 participants across Australia and the United States during 2010-14. Participants were randomized to receive either 100mg aspirin daily or matching placebo, with disability-free survival as the primary outcome. During a median 4.7 years of follow-up, 37% of participants in the aspirin group permanently ceased taking their study medication and 10% commenced open label aspirin (OLA). In the placebo group, 35% and 11% ceased study medication and commenced OLA,...
Source: Am J Epidemiol - August 8, 2023 Category: Epidemiology Authors: C L Smith J Kasza R L Woods J E Lockery B Kirpach C M Reid E Storey M R Nelson R C Shah S G Orchard M E Ernst A M Tonkin A M Murray J J McNeil R Wolfe Source Type: research
Changes in process and outcome for ST elevation myocardial infarction in central China from 2011 to 2018
CONCLUSIONS: Gradual implementation of the guideline-recommended treatments in STEMI patients from 2011 to 2018 has been associated with decreased in-hospital mortality. However, gaps persist between clinical practice and guideline recommendation. Public awareness, reperfusion strategies, and construction of chest pain centers need to be further underscored in central China.PMID:37545028 | DOI:10.1097/CM9.0000000000002698
Source: Chinese Medical Journal - August 7, 2023 Category: General Medicine Authors: You Zhang Shan Wang Datun Qi Xianpei Wang Muwei Li Zhongyu Zhu Qianqian Cheng Dayi Hu Chuanyu Gao Source Type: research
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research
Changes in process and outcome for ST elevation myocardial infarction in central China from 2011 to 2018
CONCLUSIONS: Gradual implementation of the guideline-recommended treatments in STEMI patients from 2011 to 2018 has been associated with decreased in-hospital mortality. However, gaps persist between clinical practice and guideline recommendation. Public awareness, reperfusion strategies, and construction of chest pain centers need to be further underscored in central China.PMID:37545028 | DOI:10.1097/CM9.0000000000002698
Source: Chinese Medical Journal - August 7, 2023 Category: General Medicine Authors: You Zhang Shan Wang Datun Qi Xianpei Wang Muwei Li Zhongyu Zhu Qianqian Cheng Dayi Hu Chuanyu Gao Source Type: research
Five Year Survival in Medicare Patients Undergoing Interventions for Peripheral Arterial Disease: a Retrospective Cohort Analysis of Linked Registry Claims Data
CONCLUSION: Long term survival in Medicare patients undergoing interventions in VQI centres for peripheral arterial disease is poor. Two thirds of CLTI patients and over one third of IC patients were not alive at 5 years. Intervening for IC in patients with high mortality risk should be avoided. For CLTI patients identified with decreased survival likelihood, intervention durability may be less important than invasiveness. Pre-operative medical optimisation should always be undertaken.PMID:37543356 | DOI:10.1016/j.ejvs.2023.07.055
Source: PubMed: Eur J Vasc Endovasc ... - August 5, 2023 Category: Surgery Authors: Scott R Levin Alik Farber Philip P Goodney Elizabeth G King Mohammad H Eslami Mahmoud B Malas Virendra I Patel Sharon C Kiang Jeffrey J Siracuse VQI VISION Source Type: research
